Liver Cirrhosis-Pipeline Review, H1 2016

Liver Cirrhosis-Pipeline Review, H1 2016


  • Products Id :- GMDHC7728IDB
  • |
  • Pages: 102
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Liver Cirrhosis-Pipeline Review, H1 2016', provides an overview of the Liver Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis

The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects

The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Liver Cirrhosis Overview 9

Therapeutics Development 10

Pipeline Products for Liver Cirrhosis-Overview 10

Pipeline Products for Liver Cirrhosis-Comparative Analysis 11

Liver Cirrhosis-Therapeutics under Development by Companies 12

Liver Cirrhosis-Therapeutics under Investigation by Universities/Institutes 13

Liver Cirrhosis-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Liver Cirrhosis-Products under Development by Companies 17

Liver Cirrhosis-Products under Investigation by Universities/Institutes 18

Liver Cirrhosis-Companies Involved in Therapeutics Development 19

Conatus Pharmaceuticals Inc. 19

Digna Biotech, S.L. 20

Galectin Therapeutics, Inc. 21

Gilead Sciences, Inc. 22

GNI Group Ltd. 23

Human Stem Cells Institute 24

INVENT Pharmaceuticals, Inc. 25

Nimbus Therapeutics, LLC 26

Pacific Therapeutics Ltd. 27

PharmaIN Corporation 28

Pharmicell Co., Ltd. 29

S-Evans Biosciences, Inc. 30

Stelic Institute & Co., Inc. 31

Stempeutics Research Private Limited 32

Liver Cirrhosis-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Combination Products 34

Assessment by Target 35

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 43

(sofosbuvir + velpatasvir)-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

DB-027-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

DB-036-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

emricasan-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

F-351-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Gemacell-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

GRMD-02-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

GXHPC-1-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

INV-340-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Livercellgram-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ND-654-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

PTL-303-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Stem Cell Therapy for Liver Cirrhosis-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Stempeucel-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

STNM-04-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Synthetic Peptide for Liver Cirrhosis-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

thrombopoietin-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Liver Cirrhosis-Recent Pipeline Updates 73

Liver Cirrhosis-Dormant Projects 90

Liver Cirrhosis-Discontinued Products 91

Liver Cirrhosis-Product Development Milestones 92

Featured News & Press Releases 92

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 92

Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting 93

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 94

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 94

Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting 95

Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement 95

May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 97

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 98

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 99

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 99

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Figures

Number of Products under Development for Liver Cirrhosis, H1 2016 10

Number of Products under Development for Liver Cirrhosis-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 15

Comparative Analysis by Early Stage Products, H1 2016 16

Assessment by Monotherapy Products, H1 2016 33

Number of Products by Top 10 Targets, H1 2016 35

Number of Products by Stage and Top 10 Targets, H1 2016 35

Number of Products by Top 10 Mechanism of Actions, H1 2016 37

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 37

Number of Products by Routes of Administration, H1 2016 39

Number of Products by Stage and Routes of Administration, H1 2016 39

Number of Products by Molecule Types, H1 2016 41

Number of Products by Stage and Molecule Types, H1 2016 41

List of Tables

Number of Products under Development for Liver Cirrhosis, H1 2016 10

Number of Products under Development for Liver Cirrhosis-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 13

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Clinical Stage Development, H1 2016 15

Comparative Analysis by Early Stage Development, H1 2016 16

Products under Development by Companies, H1 2016 17

Products under Investigation by Universities/Institutes, H1 2016 18

Liver Cirrhosis-Pipeline by Conatus Pharmaceuticals Inc., H1 2016 19

Liver Cirrhosis-Pipeline by Digna Biotech, S.L., H1 2016 20

Liver Cirrhosis-Pipeline by Galectin Therapeutics, Inc., H1 2016 21

Liver Cirrhosis-Pipeline by Gilead Sciences, Inc., H1 2016 22

Liver Cirrhosis-Pipeline by GNI Group Ltd., H1 2016 23

Liver Cirrhosis-Pipeline by Human Stem Cells Institute, H1 2016 24

Liver Cirrhosis-Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 25

Liver Cirrhosis-Pipeline by Nimbus Therapeutics, LLC, H1 2016 26

Liver Cirrhosis-Pipeline by Pacific Therapeutics Ltd., H1 2016 27

Liver Cirrhosis-Pipeline by PharmaIN Corporation, H1 2016 28

Liver Cirrhosis-Pipeline by Pharmicell Co., Ltd., H1 2016 29

Liver Cirrhosis-Pipeline by S-Evans Biosciences, Inc., H1 2016 30

Liver Cirrhosis-Pipeline by Stelic Institute & Co., Inc., H1 2016 31

Liver Cirrhosis-Pipeline by Stempeutics Research Private Limited, H1 2016 32

Assessment by Monotherapy Products, H1 2016 33

Assessment by Combination Products, H1 2016 34

Number of Products by Stage and Target, H1 2016 36

Number of Products by Stage and Mechanism of Action, H1 2016 38

Number of Products by Stage and Route of Administration, H1 2016 40

Number of Products by Stage and Molecule Type, H1 2016 42

Liver Cirrhosis Therapeutics-Recent Pipeline Updates, H1 2016 73

Liver Cirrhosis-Dormant Projects, H1 2016 90

Liver Cirrhosis-Discontinued Products, H1 2016 91

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Conatus Pharmaceuticals Inc. Digna Biotech, S.L. Galectin Therapeutics, Inc. Gilead Sciences, Inc. GNI Group Ltd. Human Stem Cells Institute INVENT Pharmaceuticals, Inc. Nimbus Therapeutics, LLC Pacific Therapeutics Ltd. PharmaIN Corporation Pharmicell Co., Ltd. S-Evans Biosciences, Inc. Stelic Institute & Co., Inc. Stempeutics Research Private Limited

Liver Cirrhosis Therapeutic Products under Development, Key Players in Liver Cirrhosis Therapeutics, Liver Cirrhosis Pipeline Overview, Liver Cirrhosis Pipeline, Liver Cirrhosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com